IMMP (Immutep) Treasury Stock : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 1988. Start your Free Trial

What is Immutep Treasury Stock?

Treasury stock is the portion of shares that a company keeps in their own treasury. Immutep's treasury stock for the quarter that ended in Dec. 2024 was $0.00 Mil.

Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place.

Immutep Treasury Stock Historical Data

The historical data trend for Immutep's Treasury Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Treasury Stock Chart

Immutep Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Treasury Stock

Get a 7-Day Free Trial

Immutep Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Treasury Stock	Get a 7-Day Free Trial															-	-	-	-	-

Immutep Treasury Stock Calculation

The portion of shares that a company keeps in their own treasury. Treasury stock may have come from a repurchase or buyback from shareholders; or it may have never been issued to the public in the first place. These shares don't pay dividends, have no voting rights, and should not be included in shares outstanding calculations.

Immutep Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (NAS:IMMP) » Definitions » Treasury Stock

Comparable Companies

Traded in Other Exchanges

PRRUF:USA YP1A:Germany YP1A:Germany YP1B:Germany YP1A:Germany IMM:Australia

Address

264 George Street, Level 32, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.